TMA Funded Projects

In 2002, The Myositis Association began funding research into promising studies and fellowships recommended by the Research Committee of the Medical Advisory Board and approved by the Board of Directors of The Myositis Association.  TMA has advanced the world's understanding of myositis.

To choose the best possible proposals, TMA advertises widely in professional medical journals, with medical schools, with current researchers, and through TMA's web site to reach scientists and physicians all over the world. Many more proposals are received than can be funded, but TMA seeks to fund those considered most promising.

Below are projects funded through TMA's research program:


Frederick W. Miller, MD, PhD

National Institute of Environmental Health Sciences, Potential Environmental Triggers of Myositis.

K. Nagaraju, MD

Children's Research Institute, Environment Induced Epigenetic Changes in Skeletal Muscle and Their Role in Myositis.


Christina Charles-Schoeman, MD

The quantitative and functional evaluation of lipoproteins in idiopathic inflammatory myopathies.

Arun Varadhachary, MD, PhD

Mitochondria abnormalities in dermatomyositis.


Jerry Mendell, MD

Gene therapy in sporadic inclusion-body myositis.


Jerry Mendell, MD

Gene Therapy for Sporadic Inclusion Body Myositis (Phase 2)


Eun-Ha Kang, M.D.

Characterization of CD4+CD8+ Double Positive T Cells in Dermatomyositis

Massimiliano Mirabella, M.D., PhD

Exploring a stem cell-based muscle regenerative therapy for Inclusion-Body Myositis: preclinical studies on ex vivo treat


Valerie Askanas, MD, PhD

Role of Par-y in Pathogenesis and Potential Treatment of Sporadic Inlusion-Body Myositis

Ingrid Lundberg, MD

Development and validation of classification criteria for polymyositis (PM) and dermatomyositis (DM)

Jerry Mendell, MD

Gene Therapy for Sporadic Inclusion Body Myositis

Terry Oh, MD

Application of Stance Control Orthosis in Patients with Inclusion Body Myositis

Christa Studzinski, MD

Use of Exercise and Dietary Modification as Treatments for Inclusion-Body Myositis in a Transgenic Mouse Model


Hanns Lochmueller, MD

Molecular pathogenesis of inclusion body myositis (IBM) and IMACS natural history study of IBM

Ingrid Lundberg, MD, PhD

Why are inflamed muscle weak? How does the immune system affect muscle function in patients with poly- and dermatomyositis?

Nicola Ruperto, MD

Phase II trials effectiveness trial in new onset juvenile dermatomyositis


Valerie Askanas, MD, PhD

Role of myostatin in the pathogenesis and potential treatment of sporadic inclusion-body myositis

Consuelo Lopez, MD

Role of Chimeric Dendritic cells in the inflammatory process of Juvenile Dermatomyositis

Satoshi Okada, MD

The role of granulysin in muscle fiber injury in idiopathic inflammatory myopathies

Angelo Ravelli, MD

A multicenter study of the long-term outcome of juvenile idiopathic inflammatory myopathies

Stina Salomonsson, MD

Muscle weakness experienced by patients with IIM - Is there a connection between IL-1a and muscle function?


James Jarvis, MD

Juvenile myositis in Native Americans

K. Nagaraju, MD

Mechanisms of muscle fiber damage and dysfunction in myositis

Henry Querfurth, MD

Calcium dyshomeostasis and intramyofiber b-amyloid; Mechanisms of disease pathogenesis in IBM


Carol Artlett, BSc, PhD

Characterization of Maternal Microchimeric Cells in Males with Juvenile Dermatomyositis

Valerie Askanas, MD, PhD

Pathogenic Role of Excess Cholesterol in Sporadic Inclusion-Body Myositis Muscle

Sabine Krause, MD, PhD

The MHC Processing and presentation machinery: clues for the immunopathogenesis of idiopathic inflammatory myopathies

Gulnara Mamyrova, MD

Childhood Myositis Heterogeneity Study

Lauren Pachman, MD

Are lymphocytes activated at 10 years after diagnosis of Juvenile Dermatomyositis?

Xiao-Feng Yang, MD, PhD

RNA Exosome-specific Immune Responses and Autoimmune Myositis





Updated March 2012




You can make a difference. Learn
about TMA members' campaigns to raise
funds and awareness.